Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

PSMA-PET imaging technology is leveraged to identify advanced prostate cancer. Credit: Korawat photo shoot / Shutterstock. Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix ...

Through its vast network of top urologists, oncologists, and researchers from world-class institutions, Human Longevity's $1 ...